HLugA180Su03 : Lung carcinoma,92 cases, tumor and matched NAT* with survival information.replacing Hlug-Ade150Sur-01
  • $1,406.00
Microarray Panel 1.88 cases of lung adenocarcinoma with matched adjacent normal tissue and 4 cases have tumor only, 1 core/case. 2.Clinical stage(AJCC 7.0)I II III IV, with TNM score. 3.Survival information available.
Cores 180
Biomax.com Tissue Array HLugA180Su03
Cases 92
Row number 11
Column number 18
Core Diameter (mm) 1.5
Thickness (µm) 4
Quantity Control H&E and IHC confirmed
Tissue Array Type FFPE
Species Human
Applications Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.
Notes 1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers.
Mouseover and click individual cores to view high resolution images.
Slide Label: US Biomax, Inc. Tissue Array
123456789101112131415161718
ALunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
BLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
CLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
DLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
ELunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
FLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
GLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
HLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
ILunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
JLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLunLun
K—                 
Legend: Lun - Lung, - —

- Malignant tumor, - Malignant tumor (stage —), - Malignant tumor (stage Ⅰ), - Malignant tumor (stage Ⅱ), - Malignant tumor (stage ⅡⅢ), - Malignant tumor (stage Ⅲ), - Malignant tumor (stage Ⅳ), - NAT, -

Specification Sheet (Sortable), tissue IDs are available in exported Excel files.

No.Surgery Date Survival StatusVisit DateSurvival Months
1 2008/1/15 survival 2014/3/1
2
3 2008/2/26 deseaced 2011/1/27 35
4
5 2008/4/7 survival 2014/3/1
6
7 2008/7/14 deseaced 2010/3/9 20
8
9 2008/7/15 survival 2014/3/1
10
11 2009/4/14 survival 2014/3/1
12
13 2009/6/17 deseaced 2010/5/20 11
14
15 2009/6/19 survival 2014/3/1
16
17 2009/7/13 survival 2016/6/1 83
18
19 2009/7/14 deseaced 2012/11/7 40
20
21 2009/7/31 deseaced 2016/6/18 83
22
23 2009/7/30 deseaced 2013/2/9 43
24
25 2009/9/28 deseaced 2011/1/28 16
26
27 2009/10/29 deseaced 2013/8/16 46
28
29 2009/10/5 survival 2014/3/1
30
31 2009/10/26 survival 2010/6/3
32
33 2009/11/3 deseaced 2012/7/26 33
34
35 2009/12/5 deseaced 2010/4/6 4
36
37 2009/12/15 deseaced 2013/3/12 39
38
39 2009/12/15 deseaced 2010/5/10 5
40
41 2009/12/25 survival 2014/3/1
42
43 2010/1/5 deseaced 2010/10/26 9
44
45 2010/1/14 deseaced 2012/2/27 25
46
47 2010/4/26 deseaced 2011/1/28 9
48
49 2010/5/11 survival 2016/6/1 73
50
51 2010/5/25 survival 2016/6/1 73
52
53 2010/6/9 survival 2016/6/1 72
54
55 2010/6/11 deseaced 2011/6/30 12
56
57 2010/7/15 deseaced 2010/12/14 5
58
59 2010/7/21 deseaced 2012/3/16 20
60
61 2010/7/30 survival 2016/6/1 71
62
63 2010/8/23 survival 2016/6/1 70
64
65 2010/9/13 deseaced 2013/6/1 33
66
67 2010/9/13 deseaced 2014/8/15 47
68
69 2010/10/28 deseaced 2014/4/20 42
70
71 2010/11/2 deseaced 2013/7/18 32
72
73 2010/11/25 survival 2016/8/1 67
74
75 2010/12/9 deseaced 2012/10/13 22
76
77 2010/12/16 deseaced 2013/3/9 27
78
79 2010/12/21 survival 2016/8/1 66
80
81 2010/12/31 deseaced 2014/10/30 46
82
83 2011/1/12 survival 2013/1/1
84
85 2011/1/13 deseaced 2012/5/14 16
86
87 2011/1/19 deseaced 2011/9/13 8
88
89 2011/2/1 survival 2016/8/1 64
90
91 2011/3/16 deseaced 2011/12/26 9
92
93 2011/4/21 survival 2016/8/1 62
94
95 2011/4/22 survival 2016/8/1 62
96
97 2011/6/17 deseaced 2014/9/25 39
98
99 2011/8/5 deseaced 2015/2/18 42
100
101 2011/8/9 survival 2016/8/1 58
102
103 2011/8/9 deseaced 2011/12/5 4
104
105 2011/8/24 deseaced 2013/6/19 22
106
107 2011/9/15 survival 2016/8/1 57
108
109 2011/10/11 deseaced 2012/12/24 14
110
111 2011/10/13 survival 2016/8/1 56
112
113 2011/11/1 deseaced 2012/6/14 7
114
115 2011/11/9 survival 2016/8/1 55
116
117 2011/11/18 deseaced 2014/2/21 27
118
119 2011/11/28 survival 2014/3/1
120
121 2011/12/1 survival 2016/8/1 54
122
123 2011/12/21 survival 2016/8/1 54
124
125 2011/12/20 deseaced 2012/12/26 12
126
127 2012/1/19 deseaced 2014/8/14 31
128
129 2012/3/8 survival 2014/3/1
130
131 2012/3/14 deseaced 2013/12/22 21
132
133 2012/3/22 deseaced 2015/1/2 34
134
135 2012/3/27 survival 2014/3/1
136
137 2012/3/31 deseaced 2013/6/25 15
138
139 2012/4/9 survival 2016/8/1 50
140
141 2012/5/3 deseaced 2016/3/11 46
142
143 2012/5/7 deseaced 2014/4/16 23
144
145 2012/5/17 survival 2016/8/1 49
146
147 2012/5/28 deseaced 2013/6/23 13
148
149 2012/6/6 deseaced 2016/5/11 47
150
151 2012/6/13 survival 2016/8/1 48
152
153 2012/6/13 survival 2016/8/1 48
154
155 2012/6/26 survival 2016/8/1 48
156
157 2012/7/20 deseaced 2014/11/1 28
158
159 2012/8/31 survival 2016/8/1 46
160
161 2012/9/14 deseaced 2014/6/1 21
162
163 2012/11/2 survival 2016/8/1 43
164
165 2012/11/12 deseaced 2016/4/5 41
166
167 2012/11/16 survival 2016/8/1 43
168
169 2012/12/4 survival 2016/8/1 42
170
171 2012/12/31 survival 2016/8/1 42
172
173 2013/7/18 deseaced 2014/4/2 9
174
175 2013/7/23 deseaced 2014/12/29 17
176
177 2008/6/18 survival 2014/3/1
178 2009/11/19 deseaced 2011/1/10 14
179 2011/4/6 deseaced 2014/6/25 38
180 2011/12/29 survival 2014/3/1

The American Joint Committee on Cancer (AJCC) TNM system
T groups
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: A single tumor (any size) that hasn't grown into blood vessels
T2: Either a single tumor (any size) that has grown into blood vessels, OR more than one tumor where no tumor is larger than 5 cm (about 2 inches) across
T3a: Multiple tumors with at least one tumor that is greater than 5 cm (about 2 inches) across
T3b: At least one tumor (any size) that has grown into a major branch of the large veins of the liver (the portal and hepatic veins)
T4: The tumor has grown into a nearby organ (other than the gallbladder), OR the tumor is growing into the thin layer of tissue covering the liver (called the visceral peritoneum)
N groups
NX: Regional (nearby) lymph nodes cannot be assessed.
N0: The cancer has not spread to the regional lymph nodes.
N1: The cancer has spread to the regional lymph nodes.
M groups
M0: The cancer has not spread to distant lymph nodes or other organs.
M1: The cancer has spread to distant lymph nodes or other organs.

Find overlapping cases with this tissue array: